Literature DB >> 22577087

Invasive fungal infections following liver transplantation: incidence, risk factors, survival, and impact of fluconazole-resistant Candida parapsilosis (2003-2007).

Anupama Raghuram1, Alejandro Restrepo, Saman Safadjou, Jennifer Cooley, Mark Orloff, Dwight Hardy, Sam Butler, Christine E Koval.   

Abstract

Invasive fungal infections (IFIs) are associated with a high mortality rate for liver transplantation (LT) recipients. To study the incidence of and risk factors for IFIs in LT recipients and the associated mortality rates, we retrospectively reviewed the records of first-time deceased donor LT recipients (January 2003 to December 2007). The incidence of IFIs was 12%. Non-albicans Candida species accounted for 55% of IFIs; 50% of these IFIs were Candida parapsilosis. Only 43% of Candida isolates were fluconazole-susceptible (minimum inhibitory concentration ≤ 8 μ/mL). All C. parapsilosis isolates were fluconazole-resistant, and this coincided with a surge of these isolates during a peak period of LT. Factors associated with IFIs included a creatinine level > 2 mg/mL [hazard ratio (OR) = 2.4, 95% confidence interval (CI) = 1.2-5.0, P = 0.01], a Model for End-Stage Liver Disease score > 25 (OR = 2.4, 95% CI = 1.2-4.9, P = 0.02), pretransplant fungal colonization (OR = 7.0, 95% CI = 3.2-15.3, P < 0.001), and a daily prophylactic fluconazole dosage < 200 mg (OR = 2.8, 95% CI = 1.1-7.4, P = 0.03). According to a multivariate analysis, only pretransplant fungal colonization was associated with IFIs (OR = 7.8, 95% CI = 3.9-16.2, P < 0.001). The 1-year patient survival rates with and without IFIs were 41% and 80%, respectively, and the survival rates with C. parapsilosis, other non-albicans Candida, and Candida albicans IFIs were 28%, 50%, and 75%, respectively. In conclusion, IFIs after LT (especially non-albicans Candida species and fluconazole-resistant C. parapsilosis) were associated with reduced survival. The risk factors highlight the importance of pretransplant risk assessments. The identification of pretransplant fungal colonization may allow for risk modifications before or at the time of LT. Additionally, the number of LT procedures and prophylactic strategies may affect institutional outbreaks of resistant Candida strains.
Copyright © 2012 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22577087     DOI: 10.1002/lt.23467

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  16 in total

1.  Immunity of fungal infections alleviated graft reject in liver transplantation compared with non-fungus recipients.

Authors:  Tonghai Xing; Lin Zhong; Lihui Lin; Guoqiang Qiu; Zhihai Peng
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

2.  Molecular mechanisms of fluconazole resistance in Candida parapsilosis isolates from a U.S. surveillance system.

Authors:  Nina T Grossman; Cau D Pham; Angela A Cleveland; Shawn R Lockhart
Journal:  Antimicrob Agents Chemother       Date:  2014-12-01       Impact factor: 5.191

3.  Hospital outbreak of fluconazole-resistant Candida parapsilosis: arguments for clonal transmission and long-term persistence.

Authors:  Arnaud Fekkar; Marion Blaize; Adrien Bouglé; Anne-Cécile Normand; Audrey Raoelina; Dimitri Kornblum; Laure Kamus; Renaud Piarroux; Sébastien Imbert
Journal:  Antimicrob Agents Chemother       Date:  2021-02-16       Impact factor: 5.191

Review 4.  Genetic variants of innate immune receptors and infections after liver transplantation.

Authors:  Gemma Sanclemente; Asuncion Moreno; Miquel Navasa; Francisco Lozano; Carlos Cervera
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

5.  Randomized trial of micafungin for the prevention of invasive fungal infection in high-risk liver transplant recipients.

Authors:  Faouzi Saliba; Andreas Pascher; Olivier Cointault; Pierre-François Laterre; Carlos Cervera; Jan J De Waele; Umberto Cillo; Róbert M Langer; Manuela Lugano; Bo Göran-Ericzon; Stephen Phillips; Lorraine Tweddle; Andreas Karas; Malcolm Brown; Lutz Fischer
Journal:  Clin Infect Dis       Date:  2014-12-17       Impact factor: 9.079

6.  Invasive Candida Infections in Liver Transplant Recipients: Clinical Features and Risk Factors for Mortality.

Authors:  Matteo Bassetti; Maddalena Peghin; Alessia Carnelutti; Elda Righi; Maria Merelli; Filippo Ansaldi; Cecilia Trucchi; Cristiano Alicino; Assunta Sartor; Joost Wauters; Katrien Lagrou; Carlo Tascini; Francesco Menichetti; Alessio Mesini; Francesco G De Rosa; Leonel Lagunes; Jordi Rello; Arnaldo L Colombo; Antonio Vena; Patricia Munoz; Mario Tumbarello; Gabriele Sganga; Ignacio Martin-Loeches; Claudio Viscoli
Journal:  Transplant Direct       Date:  2017-04-18

Review 7.  Echinocandins for management of invasive candidiasis in patients with liver disease and liver transplantation.

Authors:  Siang Fei Yeoh; Tae Jin Lee; Ka Lip Chew; Stephen Lin; Dennis Yeo; Sajita Setia
Journal:  Infect Drug Resist       Date:  2018-05-30       Impact factor: 4.003

8.  Molecular Characterization of Candida parapsilosis by Microsatellite Typing and Emergence of Clonal Antifungal Drug Resistant Strains in a Multicenter Surveillance in China.

Authors:  Li Zhang; Shu-Ying Yu; Sharon C-A Chen; Meng Xiao; Fanrong Kong; He Wang; Ya-Ting Ning; Min-Ya Lu; Tian-Shu Sun; Xin Hou; Meng-Lan Zhou; Wei Kang; Ge Zhang; Si-Meng Duan; Ying-Chun Xu
Journal:  Front Microbiol       Date:  2020-06-16       Impact factor: 5.640

9.  Intraportally delivered stem cell spheroids localize in the liver and protect hepatocytes against GalN/LPS-induced fulminant hepatic toxicity.

Authors:  Shobha Regmi; Shiva Pathak; Tung Pham Thanh; Tiep Tien Nguyen; Jong-Hyuk Sung; Simmyung Yook; Jong Oh Kim; Chul Soon Yong; Inho Choi; Kyoung-Oh Doh; Pil-Hoon Park; Jun-Beom Park; Yoojin Seo; Bieong-Kil Kim; Dong-Mok Lee; Ik-Jae Moon; Hyung-Sik Kim; Jee-Heon Jeong
Journal:  Stem Cell Res Ther       Date:  2019-10-16       Impact factor: 6.832

Review 10.  Management of bacterial and fungal infections in end stage liver disease and liver transplantation: Current options and future directions.

Authors:  Elda Righi
Journal:  World J Gastroenterol       Date:  2018-10-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.